Market research

Artificial Intelligence in Oncology Market

Artificial intelligence (AI) is being applied across oncology to support prevention, screening, diagnosis, pathology, imaging, treatment planning, drug discovery, clinical-trial operations, and longitudinal care.

Explore licensesfrom $3,939

Assess the study’s coverageRead the public overview, then compare the chapter outline with your research brief.

18report chapters

Public research overviewHow we research Research team

Artificial Intelligence in Oncology: Clinical Utility, Governance, and Evidence

Artificial intelligence (AI) is being applied across oncology to support prevention, screening, diagnosis, pathology, imaging, treatment planning, drug discovery, clinical-trial operations, and longitudinal care. Its value depends on clinically meaningful performance, representative data, integration with existing workflows, and evidence that use improves outcomes or efficiency without widening disparities. The field remains heterogeneous: some tools assist narrowly defined tasks, while others combine multimodal clinical, imaging, molecular, and real-world data. Responsible adoption therefore requires validation in the settings where systems will be used, clear accountability, and continuous monitoring after deployment.

360iResearch introduction

Inside the research

Coverage at a glance

Selected branches from the published table of contents. Follow a chapter to see every subchapter in context.

  1. Chapter 7 Product Type

    • Hardware
    • Services
    • Software Solutions
    View chapter
  2. Chapter 8 Technology

    • Computer Vision
    • Deep Learning
    • Machine Learning
    • Natural Language Processing
    View chapter
  3. Chapter 9 Cancer Type

    • Breast Cancer
    • Cervical Cancer
    • Colorectal Cancer
    • Esophageal Cancer
    More in this chapter

From Experimental Models to Workflow-Embedded Oncology Tools

The oncology landscape is shifting from proof-of-concept algorithms toward tools embedded in radiology, pathology, radiation oncology, surgery, medical oncology, and trial workflows. Digital pathology, quantitative imaging, structured clinical data, and genomic information are enabling more reproducible analysis, while cloud infrastructure and interoperable records can support collaboration across institutions. At the same time, regulators and health systems are placing greater emphasis on transparency, cybersecurity, human oversight, software lifecycle management, and evidence of generalizability. Adoption is increasingly shaped not only by algorithmic accuracy, but also by usability, reimbursement, procurement standards, clinician trust, and the ability to demonstrate benefit for diverse patient populations.

AI’s Cumulative Impact: Better Detection, Personalization, and Operational Coordination

AI can help identify subtle findings, prioritize cases, quantify disease characteristics, support treatment selection, and reduce repetitive administrative work. In research, it can accelerate image analysis, biomarker discovery, patient matching, and trial recruitment. Generative and multimodal systems may improve summarization and decision support, but they introduce risks including fabricated outputs, automation bias, leakage of sensitive information, and unclear provenance. The cumulative impact will be determined by prospective evaluation, calibration across demographic and clinical groups, integration with multidisciplinary decision-making, and safeguards that preserve clinician responsibility rather than replacing it.

Regional Insights: Uneven Readiness Across North America, Europe, and Emerging AI Ecosystems

North America has strong clinical research, digital-health infrastructure, and AI development capacity, while implementation remains subject to privacy, regulatory, interoperability, and reimbursement requirements. Europe is advancing coordinated governance through data-protection and AI-regulation frameworks, but adoption must navigate varied health systems, languages, data-access rules, and evidence expectations across the European Union and neighboring markets. Asia-Pacific combines advanced capabilities in countries such as Japan, South Korea, Australia, China, and Singapore with substantial variation in infrastructure and access across the region. Latin America is developing oncology and digital-health capacity while confronting fragmented records, uneven connectivity, and limited access to high-quality annotated data. The Middle East is investing in health-system modernization and national data capabilities, whereas Africa faces major infrastructure and workforce constraints alongside opportunities to use AI for triage, screening support, and specialist access.

Group Insights: Policy Alignment and Data Collaboration Shape Collective Progress

ASEAN countries can benefit from interoperable approaches and shared validation methods while accounting for differences in language, infrastructure, and health-system maturity. BRICS cooperation offers opportunities for research, workforce development, and locally relevant datasets, although data governance and regulatory requirements differ substantially among members. The European Union provides a framework for coordinated digital-health governance, but cross-border implementation still depends on compatible standards and national evidence pathways. G7 members contribute advanced research and regulatory experience, while NATO members must also consider health-system resilience and cybersecurity. GCC states are building digitally enabled care environments and can accelerate adoption through common procurement, workforce training, and regional validation, provided privacy, accountability, and clinical safety remain central.

Country Insights: National Capabilities Must Translate into Locally Validated Care

Australia and Canada have strong research and public-health institutions, with implementation dependent on rural access, indigenous-data governance, and health-system integration. The United States has extensive AI research and clinical infrastructure but faces complex regulatory, reimbursement, privacy, and interoperability challenges. China is advancing medical AI, imaging, and digital platforms under a distinctive data and regulatory environment. Japan and South Korea combine sophisticated technology sectors with aging-population needs and established hospital systems. India, Brazil, Mexico, and Russia have substantial clinical demand and growing technical capacity, but regional disparities, fragmented data, and workforce constraints affect deployment. France, Germany, Italy, Spain, and the United Kingdom are developing AI-enabled oncology within regulated health systems, where evidence, procurement, privacy, and cross-institution interoperability are decisive.

Action Agenda for Oncology Leaders: Prove Value, Govern Risk, and Build Trust

Leaders should begin with clearly defined clinical problems for which AI can improve decisions, timeliness, quality, or access, then establish prospective evaluation plans before broad deployment. Build multidisciplinary governance involving clinicians, patients, data-protection specialists, information-security teams, ethicists, and procurement leaders. Require representative training and validation data, subgroup performance analysis, calibration checks, explainable documentation, audit trails, and procedures for human override. Use interoperable standards and privacy-preserving data practices to support collaboration without unnecessary data exposure. Monitor drift, errors, workload effects, disparities, and patient outcomes after implementation, and link continued use to predefined clinical and operational metrics. Workforce education should emphasize appropriate reliance, limitations, and escalation pathways.

Research Methodology: Evidence-Based Synthesis of AI Applications in Oncology

This executive summary uses a structured review of publicly available evidence from peer-reviewed research, clinical and health-system studies, regulatory and policy documents, professional guidance, and authoritative institutional sources. Findings are organized around clinical applications, technology shifts, governance, regional conditions, and cross-country implementation factors. Evidence is interpreted cautiously because performance can vary with disease prevalence, equipment, clinical workflow, data quality, and population composition. The synthesis excludes unsupported commercial claims and does not infer clinical benefit from technical accuracy alone. Particular attention is given to external validation, prospective evaluation, fairness, privacy, cybersecurity, interoperability, and post-deployment monitoring.

Conclusion: Sustainable Oncology AI Requires Evidence, Equity, and Accountable Integration

AI is becoming a practical component of oncology research and care, but its contribution will depend on disciplined implementation rather than technical novelty alone. The strongest opportunities lie in augmenting clinicians, improving consistency, extending specialist capacity, and connecting fragmented data across the cancer pathway. Sustainable progress requires locally relevant validation, transparent governance, secure infrastructure, interoperable systems, and meaningful involvement of patients and professionals. Organizations that pair innovation with continuous evaluation and equity safeguards will be better positioned to realize clinical value while limiting preventable harm.

Research report

Table of contents

  1. 1.Preface
    1. 1.1Objectives of the Study
    2. 1.2Market Definition
    3. 1.3Market Segmentation & Coverage
    4. 1.4Years Considered for the Study
    5. 1.5Currency Considered for the Study
    6. 1.6Language Considered for the Study
    7. 1.7Key Stakeholders
  2. 2.Research Methodology
    1. 2.1Introduction
    2. 2.2Research Design
      1. 2.2.1Primary Research
      2. 2.2.2Secondary Research
    3. 2.3Research Framework
      1. 2.3.1Qualitative Analysis
      2. 2.3.2Quantitative Analysis
    4. 2.4Market Size Estimation
      1. 2.4.1Top-Down Approach
      2. 2.4.2Bottom-Up Approach
    5. 2.5Data Triangulation
    6. 2.6Research Outcomes
    7. 2.7Research Assumptions
    8. 2.8Research Limitations
  3. 3.Executive Summary
    1. 3.1Introduction
    2. 3.2CXO Perspective
    3. 3.3New Revenue Opportunities
    4. 3.4Next-Generation Business Models
    5. 3.5Industry Roadmap
  4. 4.Market Overview
    1. 4.1Introduction
    2. 4.2Industry Ecosystem & Value Chain Analysis
      1. 4.2.1Supply-Side Analysis
      2. 4.2.2Demand-Side Analysis
      3. 4.2.3Stakeholder Analysis
    3. 4.3Market Dynamics
      1. 4.3.1Key Drivers
      2. 4.3.2Key Restraints
      3. 4.3.3Key Opportunities
      4. 4.3.4Key Challenges
    4. 4.4Porter’s Five Forces Analysis
    5. 4.5PESTLE Analysis
    6. 4.6Market Outlook
      1. 4.6.1Near-Term Market Outlook (0–2 Years)
      2. 4.6.2Medium-Term Market Outlook (3–5 Years)
      3. 4.6.3Long-Term Market Outlook (5–10 Years)
    7. 4.7Go-to-Market Strategy
  5. 5.Market Insights
    1. 5.1Consumer Insights & End-User Perspective
    2. 5.2Consumer Experience Benchmarking
    3. 5.3Opportunity Mapping
    4. 5.4Distribution Channel Analysis
    5. 5.5Pricing Trend Analysis
    6. 5.6Regulatory Compliance & Standards Framework
    7. 5.7ESG & Sustainability Analysis
    8. 5.8Disruption & Risk Scenarios
    9. 5.9Return on Investment & Cost-Benefit Analysis
  6. 6.Cumulative Impact of Artificial Intelligence 2026
  7. 7.Artificial Intelligence in Oncology Market, by Product Type
    1. 7.1Introduction
    2. 7.2Hardware
      1. 7.2.1Diagnostic Imaging Systems
      2. 7.2.2Robotic Surgical Systems
    3. 7.3Services
      1. 7.3.1Consulting Services
      2. 7.3.2Implementation Services
    4. 7.4Software Solutions
  8. 8.Artificial Intelligence in Oncology Market, by Technology
    1. 8.1Introduction
    2. 8.2Computer Vision
    3. 8.3Deep Learning
    4. 8.4Machine Learning
    5. 8.5Natural Language Processing
  9. 9.Artificial Intelligence in Oncology Market, by Cancer Type
    1. 9.1Introduction
    2. 9.2Breast Cancer
    3. 9.3Cervical Cancer
    4. 9.4Colorectal Cancer
    5. 9.5Esophageal Cancer
    6. 9.6Liver Cancer
    7. 9.7Lung Cancer
    8. 9.8Skin Cancer
    9. 9.9Stomach (Gastric) Cancer
    10. 9.10Thyroid Cancer
  10. 10.Artificial Intelligence in Oncology Market, by Application
    1. 10.1Introduction
    2. 10.2Diagnostics
      1. 10.2.1Imaging Analytics
      2. 10.2.2Molecular Diagnostics
      3. 10.2.3Pathology
    3. 10.3Drug Discovery
      1. 10.3.1Clinical Trials Design
      2. 10.3.2Lead Discovery
      3. 10.3.3Target Identification
    4. 10.4Outcome Prediction
      1. 10.4.1Complication Prediction
      2. 10.4.2Response Prediction
      3. 10.4.3Survival Rate Visualization
    5. 10.5Personalized Medicine
      1. 10.5.1Biomarker Identification
      2. 10.5.2Genomic Data Analysis
      3. 10.5.3Therapeutic Optimization
    6. 10.6Treatment Planning
      1. 10.6.1Chemotherapy Planning
      2. 10.6.2Surgical Planning
  11. 11.Artificial Intelligence in Oncology Market, by End User
    1. 11.1Introduction
    2. 11.2Diagnostic Centers
    3. 11.3Hospitals & Clinics
    4. 11.4Pharma & Biotech Companies
    5. 11.5Research Institutes & Organizations
  12. 12.Artificial Intelligence in Oncology Market, by Deployment Mode
    1. 12.1Introduction
    2. 12.2Cloud
    3. 12.3On Premise
  13. 13.Artificial Intelligence in Oncology Market, by Region
    1. 13.1Introduction
    2. 13.2Asia-Pacific
    3. 13.3North America
    4. 13.4Latin America
    5. 13.5Europe
    6. 13.6Middle East
    7. 13.7Africa
  14. 14.Artificial Intelligence in Oncology Market, by Group
    1. 14.1Introduction
    2. 14.2ASEAN
    3. 14.3GCC
    4. 14.4European Union
    5. 14.5BRICS
    6. 14.6G7
    7. 14.7NATO
  15. 15.Artificial Intelligence in Oncology Market, by Country
    1. 15.1Introduction
    2. 15.2United States
    3. 15.3China
    4. 15.4Germany
    5. 15.5Japan
    6. 15.6India
    7. 15.7United Kingdom
    8. 15.8France
    9. 15.9Italy
    10. 15.10Brazil
    11. 15.11Canada
    12. 15.12Mexico
    13. 15.13Russia
    14. 15.14Spain
    15. 15.15Australia
    16. 15.16South Korea
  16. 16.Competitive Landscape
    1. 16.1Market Share Analysis, 2025
    2. 16.2Market Concentration Analysis, 2025
      1. 16.2.1Concentration Ratio (CR)
      2. 16.2.2Herfindahl Hirschman Index (HHI)
    3. 16.3Recent Developments & Impact Analysis, 2025
    4. 16.4Product Portfolio Analysis, 2025
    5. 16.5Benchmarking Analysis, 2025
  17. 17.Company Profiles
    1. 17.1Amazon Web Services, Inc.
    2. 17.2AstraZeneca PLC
    3. 17.3Azra AI
    4. 17.4Bayer AG
    5. 17.5BPGbio, Inc.
    6. 17.6Bristol-Myers Squibb Company
    7. 17.7Butterfly Network, Inc.
    8. 17.8ConcertAI LLC
    9. 17.9Elekta AB
    10. 17.10F. Hoffmann-La Roche Ltd.
    11. 17.11Flatiron Health, Inc.
    12. 17.12Freenome Holdings, Inc.
    13. 17.13GE Healthcare
    14. 17.14Google LLC by Alphabet Inc.
    15. 17.15Intel Corporation
    16. 17.16International Business Machines Corporation
    17. 17.17Koninklijke Philips N.V.
    18. 17.18Lunit Inc.
    19. 17.19Medial EarlySign Ltd.
    20. 17.20Microsoft Corporation
    21. 17.21Novartis AG
    22. 17.22NVIDIA Corporation
    23. 17.23Oncora Medical, Inc.
    24. 17.24Paige.AI Inc.
    25. 17.25Panakeia Technologies LTD
    26. 17.26PathAI, Inc.
    27. 17.27Rakovina Therapeutics Inc.
    28. 17.28Siemens Healthineers AG
    29. 17.29Tempus AI, Inc.
    30. 17.30Ultromics Limited
    31. 17.31Viz.ai, Inc.
    32. 17.32Zebra Medical
  18. 18.Key Experts
Licensesfrom $3,939

Loading the sample request form…